Status:
WITHDRAWN
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Brain Neoplasms
Eligibility:
All Genders
1-21 years
Phase:
PHASE1
Brief Summary
Background: \- The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells. However, it has been used in only a s...
Detailed Description
Background: * Notch signaling is aberrantly activated in a variety of human tumors including solid tumors and hematological malignancies including T-cell leukemia (T-ALL) and pediatric cancers, such ...
Eligibility Criteria
Inclusion
- ELIGIBILITY CRITERIA:
- Patients greater than 12 months and less than or equal to 21 years of age with a diagnosis and histologic verification (except patients with intrinsic brain stem tumors, optic pathway gliomas) of measureable or evaluable relapsed or refractory disease. Current disease state must be one for which there is no known curative therapy, or therapy proven to prolong survival with an acceptable quality of life.
- Subjects must be able to swallow tablets.
- Patients who are pregnant, are known to be serologically positive for Hepatitis A, B, C, or have a history of liver disease, or have prolonged QTc are not eligible.
Exclusion
Key Trial Info
Start Date :
October 8 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 13 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01236586
Start Date
October 8 2010
End Date
April 13 2011
Last Update
July 2 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
2
St. Jude Childrens Research Hospital
Memphis, Tennessee, United States, 38105